{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:05:22Z","timestamp":1772708722150,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>TAFRO syndrome is a rare disorder that causes thrombocytopenia, generalized oedema, fever, organ enlargement, and renal impairment.<\/jats:p>\n                <jats:p>Few reports have suggested an association with vaccines, and few cases have undergone renal biopsy. TAFRO syndrome is often severe and fatal, and its cause is unknown. We report a case of TAFRO syndrome that occurred after vaccination with the coronavirus disease 2019 (COVID-19) vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 82-year-old woman received two doses of the BNT162b2 mRNA vaccine 3\u00a0weeks apart. Two weeks later, she was admitted to the hospital with oedema, accompanied with renal failure and thrombocytopenia. After close examination, she was diagnosed with TAFRO syndrome. She was treated with steroids, cyclosporine, and thrombopoietin receptor agonists.<\/jats:p>\n                <jats:p>The patient was discharged after several months in remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although an incident of TAFRO syndrome after COVID-19 vaccination has been previously reported, this is a rare case in which the patient went into remission and was discharged. A renal biopsy was also performed in this case, which was consistent with previous reports.<\/jats:p>\n                <jats:p>The favorable treatment course for TAFRO syndrome provides valuable insights.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-024-03630-x","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:02:21Z","timestamp":1718780541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of TAFRO syndrome after vaccination, successfully treated with cyclosporine"],"prefix":"10.1186","volume":"25","author":[{"given":"Yasuyuki","family":"Mimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shioko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"3630_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","volume":"111","author":"Y Masaki","year":"2020","unstructured":"Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155\u20138.","journal-title":"Int J Hematol"},{"key":"3630_CR2","first-page":"320","volume":"51","author":"K Takai","year":"2010","unstructured":"Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320\u20135.","journal-title":"Rinsho Ketsueki"},{"key":"3630_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00277-022-04762-6","volume":"101","author":"Y Masaki","year":"2022","unstructured":"Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022;101:485\u201390.","journal-title":"Ann Hematol"},{"issue":"10","key":"3630_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","volume":"96","author":"Y Nishimura","year":"2021","unstructured":"Nishimura Y, Faigenbaum DC, Pierson SK, et al. Validated international definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96(10):1241\u201352.","journal-title":"Am J Hematol"},{"key":"3630_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.25554","volume":"94","author":"S Fujimoto","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975\u201383.","journal-title":"Am J Hematol"},{"key":"3630_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12185-021-03159-x","volume":"114","author":"H Kawabata","year":"2021","unstructured":"Kawabata H, Fujimoto S, Sakai T, et al. Patient\u2019s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179\u201388.","journal-title":"Int J Hematol"},{"issue":"20","key":"3630_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115\u201324.","journal-title":"Blood"},{"issue":"3","key":"3630_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bcmd.2015.06.013","volume":"55","author":"A Allegra","year":"2015","unstructured":"Allegra A, Rotondo F, Russo S, et al. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis. 2015;55(3):206\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"3630_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12882-022-02886-5","volume":"23","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki T, Kuragano T, et al. TAFRO syndrome with renal biopsy successfully treated with steroids and cyclosporine: a case report. BMC Nephrol. 2022;23:262.","journal-title":"BMC Nephrol"},{"issue":"2","key":"3630_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/mrcr\/rxad020","volume":"7","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Haji Y, Hozumi M, et al. Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sj\u00f6gren\u2019s syndrome: A case report. Mod Rheumatol Case Rep. 2023;7(2):475\u20139.","journal-title":"Mod Rheumatol Case Rep."},{"issue":"5","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.19000","volume":"203","author":"X Yin","year":"2023","unstructured":"Yin X, Liu Y, Zhong C, et al. Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice. Br J Haematol. 2023;203(5):803\u20136.","journal-title":"Br J Haematol"},{"issue":"48","key":"3630_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032200","volume":"101","author":"T Kakutani","year":"2022","unstructured":"Kakutani T, Nunokawa T, Chinen N, et al. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine. 2022;101(48): e32200.","journal-title":"Medicine"},{"issue":"21","key":"3630_CR13","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1182\/bloodadvances.2023010745","volume":"7","author":"SK Pierson","year":"2023","unstructured":"Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv. 2023;7(21):6652\u201364.","journal-title":"Blood Adv"},{"issue":"20","key":"3630_CR14","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, Foss\u00e5 A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115\u201324.","journal-title":"Blood"},{"issue":"16","key":"3630_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353\u201364.","journal-title":"Blood"},{"issue":"10","key":"3630_CR16","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/10428194.2022.2074992","volume":"63","author":"A Sakaki","year":"2022","unstructured":"Sakaki A, Hosoi H, Kosako H, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma. 2022;63(10):2499\u2013502.","journal-title":"Leuk Lymphoma"},{"key":"3630_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric castleman disease. Am J Hematol. 2016;91:220\u20136.","journal-title":"Am J Hematol"},{"key":"3630_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006271","volume":"96","author":"FF Jos\u00e9","year":"2017","unstructured":"Jos\u00e9 FF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin DDC, Malheiros DMAC, et al. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine. 2017;96: e6271.","journal-title":"Medicine"},{"key":"3630_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13730-018-0338-x","volume":"7","author":"T Ozeki","year":"2018","unstructured":"Ozeki T, Tsuji M, Yamamoto J, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7:243\u20137.","journal-title":"CEN Case Rep"},{"key":"3630_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.humpath.2018.03.021","volume":"82","author":"H Mizuno","year":"2018","unstructured":"Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258\u201363.","journal-title":"Hum Pathol"},{"key":"3630_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13730-018-0319-0","volume":"7","author":"S Noda-Narita","year":"2018","unstructured":"Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7:162\u20138.","journal-title":"CEN Case Rep"},{"key":"3630_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2169\/internalmedicine.9556-17","volume":"57","author":"A Nakamori","year":"2018","unstructured":"Nakamori A, Akagaki F, Yamaguchi Y, Arima R, Sugiura T. Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly. Intern Med. 2018;57:1123\u20139.","journal-title":"Intern Med"},{"key":"3630_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008216","volume":"96","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine. 2017;96: e8216.","journal-title":"Medicine"},{"key":"3630_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ekir.2020.05.004","volume":"5","author":"H Mizuno","year":"2020","unstructured":"Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5:1172\u20139.","journal-title":"Kidney Int Rep"},{"key":"3630_CR25","doi-asserted-by":"crossref","unstructured":"Furuto Y, Hashimoto H, et al. Membranoproliferative glomerulonephritis-like finding for TAFRO syndrome, associated with an anterior mediastinal tumor. Medicine. 2018;97(24):e11057.","DOI":"10.1097\/MD.0000000000011057"},{"key":"3630_CR26","doi-asserted-by":"crossref","unstructured":"Leurs A, Gnemmi V, Terriou L, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol. 2019:10:1489.","DOI":"10.3389\/fimmu.2019.01489"},{"key":"3630_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13730-019-00400-9","volume":"8","author":"H Saito","year":"2019","unstructured":"Saito H, Tanaka K, Kazama J, et al. Pathological finding of progressive renal involvement in a patient with TAFRO syndrome. CEN case report. 2019;8:239\u201345.","journal-title":"CEN case report"},{"key":"3630_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12882-019-1574-9","volume":"20","author":"Y Nagayama","year":"2019","unstructured":"Nagayama Y, Yamato M, Matsui K, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.","journal-title":"BMC Nephrol"},{"key":"3630_CR29","doi-asserted-by":"publisher","first-page":"e234155","DOI":"10.1136\/bcr-2019-234155","volume":"13","author":"SR Simeni Njonnou","year":"2020","unstructured":"Simeni Njonnou SR, Deuson J, et al. Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Report. 2020;13:e234155.","journal-title":"BMJ Case Report."},{"issue":"1","key":"3630_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12882-020-02119-7","volume":"21","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Xhang Y, et al. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol. 2020;21(1):499.","journal-title":"BMC Nephrol"},{"key":"3630_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.xkme.2020.10.011","volume":"2","author":"K Shimada","year":"2021","unstructured":"Shimada K, Sasaki T, Okabe M, et al. TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med. 2021;2:286\u201393.","journal-title":"Kidney Med"},{"key":"3630_CR32","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2169\/internalmedicine.0529-22","volume":"62","author":"Y Nakayama","year":"2023","unstructured":"Nakayama Y, Mizuno H, Ubara Y, et al. Adolescent-onset TAFRO syndrome with malignant nephrosclerosis-like lesions. Intern Med. 2023;62:2223\u20139.","journal-title":"Intern Med"},{"key":"3630_CR33","doi-asserted-by":"publisher","first-page":"1266187","DOI":"10.3389\/fimmu.2023.1266187","volume":"14","author":"H Sato","year":"2023","unstructured":"Sato H, Kanno A, Fukukawa K, et al. Case report: acase of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. Front Immunol. 2023;14:1266187.","journal-title":"Front Immunol"},{"key":"3630_CR34","first-page":"29","volume":"70","author":"S Naomi","year":"2022","unstructured":"Naomi S, Takashi Y, Kensuke T, Hiruta H, Tomoaki MA, Ichiro T. A case of tafro syndrome who showed remarkable elevation of presepsin level without an apparent infectious disease. J Jpn Soc Lab Med. 2022;70:29\u201334.","journal-title":"J Jpn Soc Lab Med"},{"key":"3630_CR35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jiac.2022.04.005","volume":"28","author":"M Yamada","year":"2022","unstructured":"Yamada M, Sada RM, Kashihara E, Okubo G, Matsushita S, Manabe A, et al. TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report. J Infect Chemother. 2022;28:1008\u201311.","journal-title":"J Infect Chemother"},{"key":"3630_CR36","first-page":"7292895","volume":"2023","author":"H Hirose","year":"2023","unstructured":"Hirose H, Suzuki H, Umezawa Y, et al. A case of TAFRO syndrome developed after COVID-19 vaccination. Case Rep Nephrol. 2023;2023:7292895.","journal-title":"Case Rep Nephrol"},{"key":"3630_CR37","doi-asserted-by":"crossref","unstructured":"Hoffmann C, Wechselberger T, Drexel H, et al. Idiopathic multicentric Castleman disease occurring shortly after mRNA SARS-CoV-2 vaccine. Vaccines. 2022;10(10):1725.","DOI":"10.3390\/vaccines10101725"},{"key":"3630_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejphar.2019.04.045","volume":"854","author":"S Zhao","year":"2019","unstructured":"Zhao S, Gao N, Qi H, Chi H, Liu B, He B, et al. Suppressive effects of sunitinib on a TLR activation-induced cytokine storm. Eur J Pharmacol. 2019;854:347\u201353.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"3630_CR39","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, lgyarto BZ, et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479.","journal-title":"iScience"},{"key":"3630_CR40","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1016\/j.vaccine.2021.01.054","volume":"39","author":"TP Vogel","year":"2021","unstructured":"Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C\/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39:3037\u201349.","journal-title":"Vaccine"},{"key":"3630_CR41","doi-asserted-by":"publisher","first-page":"E1341","DOI":"10.1503\/cmaj.211212","volume":"193","author":"J Robichaud","year":"2021","unstructured":"Robichaud J, C\u00f4t\u00e9 C, C\u00f4t\u00e9 F. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-Astrazeneca) vaccination. CMAJ. 2021;193:E1341\u20134.","journal-title":"CMAJ"},{"key":"3630_CR42","volume":"25","author":"H Akiyama","year":"2021","unstructured":"Akiyama H, Kakiuchi S, Rikitake J, Matsuba H, Sekinada D, Kozuki Y, et al. Immune thrombocytopenia associated with Pfizer-BioNTech\u2019s BNT162b2 mRNA COVID-19 vaccine. ID Cases. 2021;25: e01245.","journal-title":"ID Cases"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03630-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:06:34Z","timestamp":1718780794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03630-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03630-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for ethics approval and consent for this case report were waived by the Ethics Committee of Hyogo Medical University in view of the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Ethics Committee Review Board of Konan Medical Center waives the requirement that a physician should obtain a patient\u2019s signature as the informed consents process for publication including information and images in case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}